Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The real-time risk premium for crude oil is $18/bbl, corresponding to estimate of impact of six-week full halt to tanker traffic in Strait of Hormuz

    80% confidence
  • Four of six tanks at Saudi Arabia's Ras Tanura refinery were full, and Ju'aymah terminal on country's east coast is quickly running out of spare capacity

    80% confidence
  • We will set fire to any ship attempting to pass through the strait

    80% confidence
  • Upgraded Target to outperform from market perform with price target of $145

    80% confidence
  • Proposed 15% tariffs on goods imported into US may take effect this week

    80% confidence
  • Initiated coverage on nLight with recommendation of outperform and price target of $95

    80% confidence
  • It's important to drive inflation back to target

    80% confidence
  • Fed policy could be on hold for quite some time

    80% confidence
  • Excluding Magnificent Seven megacap technology stocks, Q4 earnings expected to increase by 4.6%

    80% confidence
  • Iranian operatives from Ministry of Intelligence used backchannels to contact CIA a day after US-Israeli attacks began

    80% confidence
  • Downgraded Frontline to hold from buy

    80% confidence
  • S&P earnings growth expected to climb by 8.4% in Q4, marking tenth consecutive quarter of year-over-year growth

    80% confidence
  • Upgraded Dow to overweight from sector weight with price target of $38

    80% confidence
  • US will ensure the free flow of energy through the Strait of Hormuz with insurance guarantees and even naval escorts

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com